Avapritinib reduced cutaneous symptoms and mast cell (MC) burden in patients (pts) with indolent systemic mastocytosis (ISM) in the PIONEER study

被引：0

作者：

Hartmann, K. ^{[1
]}

Broesby-Olsen, S. ^{[2
]}

Siebenhaar, F. ^{[3
,4
,5
,6
]}

Elberink, H. O. ^{[7
]}

Gotlib, J. ^{[8
]}

Sabato, V ^{[9
,10
]}

Castells, M. ^{[11
]}

Deininger, M. W. ^{[12
]}

Heaney, M. L. ^{[13
]}

George, T., I ^{[11
,12
]}

Radia, D. H. ^{[14
]}

Triggiani, M. ^{[15
]}

Van Daele, P. ^{[16
]}

Deangelo, D. J. ^{[17
]}

Schmidt-Kittler, O. ^{[18
]}

Lin, H. ^{[18
]}

Morrison, A. ^{[18
]}

Mar, B. ^{[18
]}

Akin, C. ^{[19
]}

Maurer, M. ^{[3
,4
,5
,6
]}

机构：

[1] Univ Basel, Basel, Switzerland

[2] Odense Univ Hosp, Odense, Denmark

[3] Charite Univ Med Berlin, Berlin, Germany

[4] Free Univ Berlin, Berlin, Germany

[5] Humboldt Univ, Berlin, Germany

[6] Berlin Inst Hlth, Berlin, Germany

[7] Univ Med Ctr Groningen, Groningen, Netherlands

[8] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA

[9] Univ Antwerp, Antwerp, Belgium

[10] Antwerp Univ Hosp, Antwerp, Belgium

[11] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[12] Univ Utah, Salt Lake City, UT USA

[13] Columbia Univ, Med Ctr, New York, NY USA

[14] Guys & St Thomass NHS Fdn Trust, London, England

[15] Univ Salerno, Salerno, Italy

[16] Erasmus MC, Rotterdam, Netherlands

[17] Dana Farber Canc Inst, Boston, MA 02115 USA

[18] Blueprint Med Corp, Cambridge, MA USA

[19] Univ Michigan, Ann Arbor, MI 48109 USA

来源：

ALLERGY | 2020年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1832

引用

页码：111 / 111

页数：1

共 33 条

[31] Liquid Biopsy Enhances Diagnostic Workup of Hereditary Alpha-Tryptasemia (HaT) and Systemic Mastocytosis (SM) in Patients with Mast Cell-Mediated Symptoms and Elevated Basal Tryptase Levels
Koch, Daniel
Stocker, Hannah
Wortmann, Friederike
Axt, Franziska
Khandanpour, Cyrus
Dazert, Eva
Sina, Christian
von Bubnoff, Dagmar
Von Bubnoff, Nikolas
BLOOD, 2023, 142
[32] Safety and efficacy data of AK002, an anti-siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM): Results from a first-in-human, open-label phase 1 study
Siebenhaar, F.
Bonnekoh, H.
Hawro, T.
Hawro, M. O.
Michaelis, E. G.
Rasmussen, H. S.
Singh, B.
Kantor, A. M.
Chang, A. T.
Maurer, M.
ALLERGY, 2019, 74 : 910 - 911
[33] A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD).
Gotlib, J. R.
Kluin-Nelemans, H.
Mauro, M. J.
Hermine, O.
Hexner, E. O.
Lipton, J. H.
Awan, F. T.
Nikolova, Z. G.
Gross, S. H.
Dutreix, C.
Dharan, B.
George, T.
Horny, P.
Akin, C.
Hartmann, K.
Valent, P.
Reiter, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 →